Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Bayer looking for a "mid-size M&A transaction" in oncology

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Jun 14, 2023 8:44pm

149 Views

Post# 35497170

RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncology

A multiple billions buyout can come fast but we need BP interested. All the pieces seem to be in place to negotiate ... results, directors to deal with BP and in my opinion all the board members ready to sell. But the price could be too low for some actually. But I'm like you Fox... could take until the end of the year.

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it